| Fareha A Nawaz, MD | |
|
9205 Sw Barnes Rd, Portland, OR 97225 | |
| (503) 216-2906 | |
| Not Available |
| Full Name | Fareha A Nawaz |
|---|---|
| Gender | Female |
| Speciality | Nephrology |
| Experience | 25 Years |
| Location | 9205 Sw Barnes Rd, Portland, Oregon |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1770702839 | NPI | - | NPPES |
| 500610168 | Medicaid | OR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | MD29099 (Oregon) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Providence St Vincent Medical Center | Portland, OR | Hospital |
| Adventist Health Portland | Portland, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Providence Health And Services Oregon | 0648183608 | 1328 |
| Northwest Renal Clinic Inc | 8628065836 | 38 |
News Archive
Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that the U.S. Food and Drug Administration has accepted the Company's investigational new drug (IND) application for autologous genetically modified T-cells expressing enhanced T cell receptors specific for MAGE A10 (MAGE-A10 T) in patients with locally advanced or metastatic non-small cell lung cancer, and that the IND is now active.
A recent survey shows health insurance plans get "lukewarm" responses while other articles examine how to choose a good plan. The Washington Post reports: "Consumers aren't that enthralled with their current insurance to begin with. In a recent Consumer Reports survey, only 64 percent of readers said they were very or completely satisfied with their plan. That's a lukewarm response and a slight drop from the 67 percent who responded the same way in CR's 2007 report."
The study, which looked at 120 people over the age of 60, found people who complained of significant memory problems but still had normal performance on memory tests had reduced gray matter density in their brains even though they weren't diagnosed with Alzheimer's disease or mild cognitive impairment (MCI).
The likely and emerging partisan clash in Congress could force GOP presidential hopeful Mitt Romney to take difficult policy positions in the fall - just as the campaign is coming to an end. Meanwhile, this week on Capitol Hill, lawmakers will wrestle with a number of health care issues.
› Verified 9 days ago
| Entity Name | Providence Health & Services Oregon |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023488343 PECOS PAC ID: 0648183608 Enrollment ID: O20031106000652 |
News Archive
Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that the U.S. Food and Drug Administration has accepted the Company's investigational new drug (IND) application for autologous genetically modified T-cells expressing enhanced T cell receptors specific for MAGE A10 (MAGE-A10 T) in patients with locally advanced or metastatic non-small cell lung cancer, and that the IND is now active.
A recent survey shows health insurance plans get "lukewarm" responses while other articles examine how to choose a good plan. The Washington Post reports: "Consumers aren't that enthralled with their current insurance to begin with. In a recent Consumer Reports survey, only 64 percent of readers said they were very or completely satisfied with their plan. That's a lukewarm response and a slight drop from the 67 percent who responded the same way in CR's 2007 report."
The study, which looked at 120 people over the age of 60, found people who complained of significant memory problems but still had normal performance on memory tests had reduced gray matter density in their brains even though they weren't diagnosed with Alzheimer's disease or mild cognitive impairment (MCI).
The likely and emerging partisan clash in Congress could force GOP presidential hopeful Mitt Romney to take difficult policy positions in the fall - just as the campaign is coming to an end. Meanwhile, this week on Capitol Hill, lawmakers will wrestle with a number of health care issues.
› Verified 9 days ago
| Entity Name | Providence Health & Services Oregon |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114015971 PECOS PAC ID: 9335057447 Enrollment ID: O20031117000153 |
News Archive
Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that the U.S. Food and Drug Administration has accepted the Company's investigational new drug (IND) application for autologous genetically modified T-cells expressing enhanced T cell receptors specific for MAGE A10 (MAGE-A10 T) in patients with locally advanced or metastatic non-small cell lung cancer, and that the IND is now active.
A recent survey shows health insurance plans get "lukewarm" responses while other articles examine how to choose a good plan. The Washington Post reports: "Consumers aren't that enthralled with their current insurance to begin with. In a recent Consumer Reports survey, only 64 percent of readers said they were very or completely satisfied with their plan. That's a lukewarm response and a slight drop from the 67 percent who responded the same way in CR's 2007 report."
The study, which looked at 120 people over the age of 60, found people who complained of significant memory problems but still had normal performance on memory tests had reduced gray matter density in their brains even though they weren't diagnosed with Alzheimer's disease or mild cognitive impairment (MCI).
The likely and emerging partisan clash in Congress could force GOP presidential hopeful Mitt Romney to take difficult policy positions in the fall - just as the campaign is coming to an end. Meanwhile, this week on Capitol Hill, lawmakers will wrestle with a number of health care issues.
› Verified 9 days ago
| Entity Name | Providence Health & Services Oregon |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093976243 PECOS PAC ID: 3476450560 Enrollment ID: O20031217000186 |
News Archive
Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that the U.S. Food and Drug Administration has accepted the Company's investigational new drug (IND) application for autologous genetically modified T-cells expressing enhanced T cell receptors specific for MAGE A10 (MAGE-A10 T) in patients with locally advanced or metastatic non-small cell lung cancer, and that the IND is now active.
A recent survey shows health insurance plans get "lukewarm" responses while other articles examine how to choose a good plan. The Washington Post reports: "Consumers aren't that enthralled with their current insurance to begin with. In a recent Consumer Reports survey, only 64 percent of readers said they were very or completely satisfied with their plan. That's a lukewarm response and a slight drop from the 67 percent who responded the same way in CR's 2007 report."
The study, which looked at 120 people over the age of 60, found people who complained of significant memory problems but still had normal performance on memory tests had reduced gray matter density in their brains even though they weren't diagnosed with Alzheimer's disease or mild cognitive impairment (MCI).
The likely and emerging partisan clash in Congress could force GOP presidential hopeful Mitt Romney to take difficult policy positions in the fall - just as the campaign is coming to an end. Meanwhile, this week on Capitol Hill, lawmakers will wrestle with a number of health care issues.
› Verified 9 days ago
| Entity Name | Providence Health & Services Oregon |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568547503 PECOS PAC ID: 5294623245 Enrollment ID: O20040310000315 |
News Archive
Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that the U.S. Food and Drug Administration has accepted the Company's investigational new drug (IND) application for autologous genetically modified T-cells expressing enhanced T cell receptors specific for MAGE A10 (MAGE-A10 T) in patients with locally advanced or metastatic non-small cell lung cancer, and that the IND is now active.
A recent survey shows health insurance plans get "lukewarm" responses while other articles examine how to choose a good plan. The Washington Post reports: "Consumers aren't that enthralled with their current insurance to begin with. In a recent Consumer Reports survey, only 64 percent of readers said they were very or completely satisfied with their plan. That's a lukewarm response and a slight drop from the 67 percent who responded the same way in CR's 2007 report."
The study, which looked at 120 people over the age of 60, found people who complained of significant memory problems but still had normal performance on memory tests had reduced gray matter density in their brains even though they weren't diagnosed with Alzheimer's disease or mild cognitive impairment (MCI).
The likely and emerging partisan clash in Congress could force GOP presidential hopeful Mitt Romney to take difficult policy positions in the fall - just as the campaign is coming to an end. Meanwhile, this week on Capitol Hill, lawmakers will wrestle with a number of health care issues.
› Verified 9 days ago
| Entity Name | Northwest Renal Clinic Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679752273 PECOS PAC ID: 8628065836 Enrollment ID: O20040429000295 |
News Archive
Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that the U.S. Food and Drug Administration has accepted the Company's investigational new drug (IND) application for autologous genetically modified T-cells expressing enhanced T cell receptors specific for MAGE A10 (MAGE-A10 T) in patients with locally advanced or metastatic non-small cell lung cancer, and that the IND is now active.
A recent survey shows health insurance plans get "lukewarm" responses while other articles examine how to choose a good plan. The Washington Post reports: "Consumers aren't that enthralled with their current insurance to begin with. In a recent Consumer Reports survey, only 64 percent of readers said they were very or completely satisfied with their plan. That's a lukewarm response and a slight drop from the 67 percent who responded the same way in CR's 2007 report."
The study, which looked at 120 people over the age of 60, found people who complained of significant memory problems but still had normal performance on memory tests had reduced gray matter density in their brains even though they weren't diagnosed with Alzheimer's disease or mild cognitive impairment (MCI).
The likely and emerging partisan clash in Congress could force GOP presidential hopeful Mitt Romney to take difficult policy positions in the fall - just as the campaign is coming to an end. Meanwhile, this week on Capitol Hill, lawmakers will wrestle with a number of health care issues.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Fareha A Nawaz, MD Po Box 3158, Portland, OR 97208-3158 Ph: (503) 215-6494 | Fareha A Nawaz, MD 9205 Sw Barnes Rd, Portland, OR 97225 Ph: (503) 216-2906 |
News Archive
Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that the U.S. Food and Drug Administration has accepted the Company's investigational new drug (IND) application for autologous genetically modified T-cells expressing enhanced T cell receptors specific for MAGE A10 (MAGE-A10 T) in patients with locally advanced or metastatic non-small cell lung cancer, and that the IND is now active.
A recent survey shows health insurance plans get "lukewarm" responses while other articles examine how to choose a good plan. The Washington Post reports: "Consumers aren't that enthralled with their current insurance to begin with. In a recent Consumer Reports survey, only 64 percent of readers said they were very or completely satisfied with their plan. That's a lukewarm response and a slight drop from the 67 percent who responded the same way in CR's 2007 report."
The study, which looked at 120 people over the age of 60, found people who complained of significant memory problems but still had normal performance on memory tests had reduced gray matter density in their brains even though they weren't diagnosed with Alzheimer's disease or mild cognitive impairment (MCI).
The likely and emerging partisan clash in Congress could force GOP presidential hopeful Mitt Romney to take difficult policy positions in the fall - just as the campaign is coming to an end. Meanwhile, this week on Capitol Hill, lawmakers will wrestle with a number of health care issues.
› Verified 9 days ago
Salona Shrestha, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 4805 Ne Glisan St, Portland, OR 97213 Phone: 503-215-2392 | |
Dr. Emmanuel Trungtoan Tavan, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 2800 N Vancouver Ave, Suite 230, Portland, OR 97227 Phone: 503-413-2901 | |
Ginevra Lois Liptan, M.D. Nephrology Medicare: Not Enrolled in Medicare Practice Location: 6400 Sw Canyon Ct, Ste 100, Portland, OR 97221 Phone: 503-477-9616 Fax: 503-477-9808 | |
Donald Richard Sullivan, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 3181 Sw Sam Jackson Park Rd, Uhn67, Portland, OR 97239 Phone: 503-494-6949 | |
Dr. Victor Nguyen Pham, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 9205 Sw Barnes Rd, Portland, OR 97225 Phone: 503-216-2906 | |
Richa Uppal, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 800 Sw 13th Ave, Portland, OR 97205 Phone: 503-221-0161 Fax: 503-274-1697 | |
Reem Hasan, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 3181 Sw Sam Jackson Park Rd, Ppv 350, Portland, OR 97239 Phone: 503-494-8562 |